Please enable JavaScript
Powered by Benchmark Matribhumi Samachar English - Page 595 of 2657 -
Friday, January 02 2026 | 03:59:07 PM

Dr. Michael Lebow Healthcare Made-Easy Gran Announces Launch and Support for Future Healthcare Leaders

Atlanta, Georgia–(Newsfile Corp. – September 16, 2025) – The Dr. Michael Lebow Healthcare Made-Easy Grant, created by Dr. Michael Lebow, a board-certified vascular surgeon and founder of the Limb Preservation Center in Jonesboro, Georgia, announces the launch of its grant application process. Designed to support undergraduate students aspiring to enter …

Read More »

GoviEx Uranium Files Meeting Materials After Obtaining Interim Order

Vancouver, British Columbia–(Newsfile Corp. – September 16, 2025) – GoviEx Uranium Inc. (TSXV: GXU) (OTCQB: GVXXF) (“GoviEx“) (“GoviEx” or the “Company”) is pleased to announce that it has filed the management information circular (the “Circular”) and related materials for its special meeting of shareholders, optionholders, and warrantholders (collectively, the “Securityholders”) to be held …

Read More »

CSE Bulletin: Delist – Basin Uranium Corp. (NCLR)

Toronto, Ontario–(Newsfile Corp. – Le 16 septembre/September 2025) – Basin Uranium Corp. (“Basin”) has announced that Nexus Uranium Corp. (“Nexus”) has completed the acquisition of all the issued and outstanding common shares of Basin (the “Basin Shares”) as previously announced. Under the terms of the arrangement, 29,999,982 common shares of …

Read More »

CSE Bulletin: Delist – Nuclear Fuels Inc. (NF)

Toronto, Ontario–(Newsfile Corp. – Le 16 septembre/September 2025) – Nuclear Fuels Inc. (“NF” or “Nuclear Fuels”) has announced completion of the previously announced arrangement (the “Arrangement”) whereby Premier American Uranium Inc. (“PUR” or “Premier American Uranium”) acquired all of the issued and outstanding common shares of Nuclear Fuels (the “NF …

Read More »

Hemostemix to Present Its Clinical Data of the Treatment of Severe Angina

Calgary, Alberta–(Newsfile Corp. – September 16, 2025) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient’s own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total …

Read More »